Equity

Is HCA Healthcare, Inc. (HCA) undervalued?

$425.49−0.34% todayNYSE · USD · last traded 2026-09-14 20:00 UTC

HCA Healthcare, Inc. trades on a P/E of 15.02 against earnings growth of 13.9% a year over the last 3 years, giving a PEG ratio of 1.08 — between the 1.0 and 2.0 levels that convention treats as the middle ground.

Earnings figures are measured from HCA’s filed annual accounts, not estimated. PEG compares price to earnings growth alone — it says nothing about debt, cash generation, or what an acquirer would pay. Read it alongside the figures below rather than on its own.

PEG ratio1.08
01.02.03.0+
Convention reads below 1.0 as inexpensive relative to growth and above 2.0 as expensive, though typical ranges differ sharply by sector.
P/E ratio15.02
earnings growth (3-year CAGR)13.9%
PEG ratio1.08
Measured from HCA's filed annual accounts. Trailing, not forecast.
01

What it would cost to buy HCA

Enterprise value is what it would cost to take the whole company: every share at today’s price, plus the debt an acquirer assumes, less the cash they receive. For HCA Healthcare, Inc. that is $141.47B.

Every term below is a line item from a filed statement. The numbers beside each one open the filing it came from — balance-sheet figures arrive already scaled, so there is no “in thousands” to catch you out.

221.8M shares · 10-Q cover page

market capitalisation$94.39B
total debt$48.02B
cash & equivalents$940.0M
enterprise value$141.47B
Balance-sheet terms as reported to 2026-03-31.
Enterprise-value multiples for HCA Healthcare, Inc.
MeasureValue
Diluted earnings per shareto 2025-12-31$28.33
P/E ratioto 2025-12-3115.0
Earnings growth (3-year CAGR)to 2025-12-3113.9%
PEG ratioto 2025-12-311.1
Market capitalisationto 2026-04-27$94.39B
Total debtto 2026-03-31$48.02B
Net debtto 2026-03-31$46.96B
Enterprise valueto 2026-03-31$141.47B
EBITDA
Free cash flowto 2025-12-31$7.69B
EV / EBITDA
EV / Salesto 2025-12-311.9×
Free cash flow yieldto 2025-12-318.1%
Net debt / EBITDA
Return on capital employed

Earnings growth is measured across HCA Healthcare, Inc.’s own filed annual accounts. PEG conventionally uses forecast growth from analyst estimates; filings contain only history, so this is trailing growth and will read differently from a PEG quoted elsewhere.

Not shown, and why

EBITDA
operating income not reported for a full year.
EV / EBITDA
operating income not reported for a full year.
Net debt / EBITDA
operating income not reported for a full year.
Return on capital employed
operating income not reported for a full year.
02

Against the sector

HCA against 4 listed companies sharing its classification — Services-Medical Laboratories and related industries. A multiple means little on its own; the column that matters is the gap.

HCA compared with the median of 4 sector peers
MeasureHCASector medianDifference
EV / Sales*1.9×1.9×0.1×
Free cash flow margin10.2%9.1%+1.0%
Compared against

DGX, DVA, LH, UHS.

Medians are taken across peers where the measure could be computed, so the sample differs by row. Green marks the direction conventionally read as cheaper or stronger — it is a direction, not a recommendation. * Price-based multiples move with the market; peer figures are a snapshot taken 2026-09-09. The remaining rows come from filed statements and hold until the next reporting season.

03

Market ratios

Price-based ratios from market data. Anything drawn from a filed statement is in the enterprise-value section above, with its source.

Valuation and financial-health metrics for HCA Healthcare, Inc. (HCA)
MetricValue
Price$425.49
PEGY ratio
Dividend yield0.73%
Price / book
Price / sales
Return on equity2.0%
Profit margin
Operating margin
Debt / equity-748.54
Current ratio
Beta1.11
52-week range$353.99 – $556.52

Not reported for HCA: pegy ratio, price / book, price / sales, profit margin, operating margin, current ratio. A dash means the figure was not available from the source, not that it is zero.

04

Compare and chart

Compare HCA vs Competitors

Use the calculator below to see how HCA stacks up against other stocks in the same industry.

Enter a ticker to pull its filings and build the valuation from the statements.

Enter a ticker to begin

Quick picks:

05

About HCA’s valuation

What is the PEG ratio for HCA Healthcare, Inc. (HCA)?
HCA Healthcare, Inc. has a PEG ratio of 1.08, from a P/E of 15.02 and earnings growth of 13.9% a year measured across 3 years of filed accounts. That is between the 1.0 and 2.0 levels that convention treats as the middle ground. Note that PEG is conventionally quoted against forecast growth; this uses reported history, so it will differ from a PEG you see elsewhere.
Is HCA undervalued right now?
That depends on the measure. On PEG, HCA reads 1.08, between the 1.0 and 2.0 levels that convention treats as the middle ground. The PEG ratio compares price to earnings growth alone — it ignores debt, cash generation and asset backing, so it is a starting point rather than a conclusion. The enterprise-value measures above account for debt and cash; they often tell a different story.
What is the PEGY ratio for HCA?
The PEGY ratio for HCA Healthcare, Inc. is —. PEGY adds the dividend yield of 0.73% to the growth rate in the denominator, which gives a fairer reading of companies returning cash as income rather than growth.
Where do these HCA figures come from?
Market price and capitalisation come from live market data; earnings, growth and dividend figures come from HCA Healthcare, Inc.'s published financial statements. Every derived ratio on this page shows the arithmetic that produced it.

This page describes published financial data. It is not investment advice and makes no recommendation to buy or sell HCA.